A Phase 3, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Tolerability of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients – Month 2 Outcomes. INSPIRE: Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

N.S. Hill; J.P. Feldman; S. Sahay; D.J. Levine; R.F. Roscigno; T.A. Vaughn; T.M. Bull; on behalf of the INSPIRE study investigators

Presenter: N.S. Hill

Tufts Medical Center

LIQUIDIA TECHNOLOGIES

Relevant Financial Relationship Disclosure Statement

- **INSPIRE: A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH)**
  - Presenter: N.S. Hill, MD
  - I will discuss investigational use of the following drugs/devices: LIQ861 Dry Powder Inhalation of Treprostinil
- **The following relevant financial relationships exist related to this presentation:**
  - N.S. Hill:
    - Consultant - Liquidia Technologies
    - Grant/Research Support Institution - Actelion, Bayer, Gilead, Liquidia Technologies, Reata, United Therapeutics
    - Scientific Medical Advisor - Liquidia Technologies

Tufts UNIVERSITY | School of Medicine

In PAH, Prostacyclin Therapy (PGI2) Improves Symptoms and Limitations by Replacing Deficient Prostacyclin at the Highest Tolerable Level of Drug

Current prostacyclin-based products have clear tradeoffs



Infusion (Continuous IV or SubQ) = Effective, but… systemic toxicities, cumbersome, limitations on lifestyle

- IV poses risk of line sepsis, SubQ limited by site pain

Oral = Convenient, but… toxicities and limited symptom relief

- Increased GI side effects
- Uptitration can be challenging given side effects

Inhaled = Local delivery, but… provides limited dose range

- Due to throat, airway irritation, cough
- Inconvenient; requires assembly, cleaning, and time to administer

Source: Decision Resources, Pulmonary Hypertension Disease Landscape & Forecast, November 2018; Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension, November 2015.

Novel PRINT® Technology Results in a Uniform Size, Shape, and Chemical Composition of Treprostinil Particles

Each identical particle is within the respirable range (<5.0 microns)

Treprostinil



Treprostinil
(prostacyclin analog)

LIQ861 Dry-Powder Formulation



LIQ861 particles are between 1-2 µm wide with trefoil shape

RS00 Model 8 Dry-Powder Inhaler

Compact, disposable inhaler previously approved by FDA and EMEA

Source: Data on file.

INSPIRE Study Design

	Day 0	Week 2	Month 1	Month 2
WHO Group I (PAH) **NYHA Class II, III, and IV** N≥100	**Treatment Phase for Primary Endpoint**			
Add-Ons Prostanoid-Naïve ≤2 non-PGI oral PAH Rx	• Initiate LIQ861 26.5 mcg capsule strength dose • Increase in 26.5 mcg increments weekly to tolerance and symptom relief			
Transitions from Tyvaso® Stable doses ≥3 mo.	• Initiate with comparable dose of LIQ861 • Titrate in 26.5 mcg incremental doses to tolerance and symptom relief			
Primary Endpoint	• **Incidence of TEAEs and SAEs at 2 months**			
Exploratory Endpoints	• Sustained use after transition (Tyvaso® transitions) • 6-minute walk distance • NT-proBNP • NYHA functional class • Quality of life questionnaire/patient satisfaction with LIQ861 • Risk assessment			

PGI = prostacyclin; SAE = serious adverse event; TEAE = treatment-emergent adverse event.
Source: https://clinicaltrials.gov/ct2/show/NCT03399604. Tyvaso® is a registered trademark of United Therapeutics Corp.

Demographics and Baseline Characteristics

		Transitions (n=55)	Add-Ons (n=66)	Overall (n=121)
Sex	Female	47 (85.5%)	52 (78.8%)	99 (81.8%)
Age (years)	Mean ± SD	53 ± 14.1	55 ± 14.6	54 ± 14.3
BMI (kg/m²)	Mean ± SD	30.07 ± 7.9	29.31 ± 7.8	29.66 ± 7.8
NYHA Functional Class at Screening	Class II	43 (78.2%)	37 (56.1%)	80 (66.1%)
	Class III	12 (21.8%)	29 (43.9%)	41 (33.9%)
PAH Duration (years)	Mean ± SD	7.25 ± 5.1	4.71 ± 5.1	5.87 ± 5.2
PAH Therapy at Screening	PDE5i alone PGI2 alone ERA alone sGC alone	8 (14.5%) 6 (10.9%) 5 (9.1%) -	12 (18.2%) - 3 (4.5%) 2 (3%)	
	ERA + PDE5i ERA + sGC	35 (63.6%) 1 (1.8%)	46 (69.7%) 3 (4.5%)	

Source: data on file

Most Patients Remained on LIQ861 Through 2 Months of Treatment

Sustained Therapy at 2 Months			
	Transitions	Add-Ons	Overall
Total Patients Enrolled	55	66	121
Discontinued ≤2 Months*	5	6	11
Sustained at 2 Months	53	60	113
% Patients Sustained at 2 Months	96.4%	90.9%	93.4%

*Patients discontinued at or prior to Month 2 due to adverse events, patient choice, investigator decision, lost to follow up.
Source: data on file.

LIQ861 Dose at Month 2 in Add-On Population (n=66)

- LIQ861 initial dose: 26.5 mcg
- LIQ861 dose at Month 2: 71% patients titrated to ≥79.5 mcg



*Dose was summarized as 0 mcg if patients had discontinued or if dosing had been temporarily interrupted at the visit
Source: data on file.

LIQ861 Dose at Month 2 in Transition Population (n=55)

- **LIQ861 initial dose: 94% patients transitioned to ≥53 mcg**
- **LIQ861 dose at Month 2: 74% patients titrated to dose ≥79.5 mcg**



*Dose was summarized as 0 mcg if patients had discontinued or if dosing had been temporarily interrupted at the visit
Source: data on file.

Serious Adverse Events (SAEs) Unrelated to LIQ861

Respiratory, Thoracic, and Mediastinal disorders

- Acute pulmonary embolism*
- Shortness of breath

Injury, Poisoning and Procedural complications

- Fractured lower leg

Nervous System disorders

- Possible seizure
- Syncope

Gastrointestinal disorders

- Gastrointestinal bleed

*One patient experienced 2 SAEs.
Source: data on file.

Treatment-Emergent Adverse Events (TEAEs) Observed Were Consistent With Inhaled Prostacyclins and Were Generally Mild to Moderate in Severity

Primary Endpoint

TEAEs at Month 2 in ≥4% of Patients Receiving LIQ861	Transitions				Add-Ons				Overall			
	No. (%) Subjects	No. of Events			No. (%) Subjects	No. of Events			No. (%) Subjects	No. of Events		
		Mld	Mod	Sev		Mld	Mod	Sev		Mld	Mod	Sev
Cough	**15 (27.3)**	14	1	0	**36 (54.5)**	29	7	0	**51 (42.1)**	43	8	0
Headache	**14 (25.5)**	12	2	0	**18 (27.3)**	13	4	1	**32 (26.4)**	25	6	1
Throat irritation	**5 (9.1)**	5	0	0	**14 (21.2)**	13	1	0	**19 (15.7)**	18	1	0
Dizziness	**6 (10.9)**	5	1	0	**7 (10.6)**	7	0	0	**13 (10.7)**	12	1	0
Diarrhea	**3 (5.5)**	2	1	0	**8 (12.1)**	5	3	0	**11 (9.1)**	7	4	0
Chest discomfort	**5 (9.1)**	4	1	0	**5 (7.6)**	4	1	0	**10 (8.3)**	8	2	0
Nausea	**4 (7.3)**	3	1	0	**5 (7.6)**	3	1	1	**9 (7.4)**	6	2	1
Flushing	**1 (1.8)**	1	0	0	**5 (7.6)**	5	0	0	**6 (5.0)**	6	0	0
Dyspnea	**3 (5.5)**	2	1	0	**3 (4.5)**	2	1	0	**6 (5.0)**	4	2	0
Oropharyngeal pain	**1 (1.8)**	1	0	0	**4 (6.1)**	4	0	0	**5 (4.1)**	5	0	0

Source: data on file.

LIQ861 Met Primary Endpoint in Pivotal Phase 3 INSPIRE Study

A convenient, safe, well-tolerated option for inhaled prostacyclin therapy

- TEAEs consistent with known side effects of inhalation therapy (cough, throat irritation, and oropharyngeal pain) and prostacyclin (cough, headache, dizziness, diarrhea, chest discomfort, nausea, dyspnea, and flushing)
- Most TEAEs were mild to moderate in severity
- Eight subjects experienced TEAEs leading to study drug withdrawal or study discontinuation
- Five subjects experienced a serious TEAE, with none related to study drug
- Overall, 93% of patients remained on LIQ861 at Month 2





TEAE = treatment-emergent adverse event.
Source: data on file.

Thank You to Patients and Principal Investigators

Roblee Allen, MD	University of California Davis
Hassan Alnuaimat, MD	University of Florida
David B. Badesch, MD*	University of Colorado Denver
Remzi Bag, MD	University of Chicago
Ray Benza, MD*	Allegheny General Hospital
Todd Bull, MD*	University of Colorado Denver
Charles Burger, MD	Mayo Clinic Jacksonville
Murali Chakinala, MD	Washington University School of Medicine
Shilpa DeSouza, MD	NYU Winthrop University Hospital
Hilary DuBrock, MD	Mayo Clinic
Jean Elwing, MD	UC Health
Jeremy Feldman, MD	Arizona Pulmonary Specialists, Ltd.
Micah Fisher, MD	Emory University
Jimmy Ford, MD	University of North Carolina Chapel Hill
Verniza Franco, MD	The Ohio State University
Robert Frantz, MD*	Mayo Clinic
Nicholas Hill, MD*	Tufts University School of Medicine
Akram Khan, MD	Oregon Health and Science University
Deb Levine, MD	University of Texas Health Science Center San Antonio
Stacy Mandras, MD	Ochsner Clinic Foundation
John McConnell, MD	Kentuckiana Pulmonary Research Center, PLLC
Lana Melendres-Groves, MD	University of New Mexico Health Sciences Center
Ron Oudiz, MD	Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
Ioana Preston, MD*	Tufts University School of Medicine
Marc Pritzker, MD	University of Minnesota
Amresh Raina, MD	Allegheny General Hospital
Stuart Rich, MD	Northwestern University
Rajeev Sagger, MD	Banner University Medical Research Institute
Sandeep Sahay, MD	Houston Methodist Research Institute
Trushil Shah, MD	The University of Texas Southwestern Medical Center
Shelly Shapiro, MD	VA Greater Los Angeles Healthcare System
Oksana Shlobin, MD	Inova Health Care Services
Marc Simon, MD	UPMC
Leslie Spikes, MD	University of Kansas Medical Center Research Institute
James Tarver, MD	Florida Hospital

*INSPIRE Steering Committee

LIQUIDIA TECHNOLOGIES